Skip to main content
. Author manuscript; available in PMC: 2021 May 3.
Published in final edited form as: Biomed Pharmacother. 2020 Dec 8;133:111058. doi: 10.1016/j.biopha.2020.111058

Figure 6.

Figure 6.

GSC-specific antiproliferative effects of mitochondria-targeted FDA approved drugs. An increase in GSC number is concentration-dependently inhibited by mitochondrially-targeted FDA-approved drugs (A, D) pyrvinium pamoate; (B, E) trifluoperazine; and (C, F) mitoxantrone. Glioma stem-like cells were treated with specified concentrations of FDA-approved drugs for 48 h, and the cell viability was measured using the Cell titre-Glo ™ method. Data are presented as average ± std. dev from 3 independent experiments (N=3).